Beta Bionics, Inc.

NASDAQ:BBNX

Medical - Equipment & Services

Healthcare
$14.33 +3.18%

+$0.42 today

Market cap
$644.70M
Beta
3.39
P/E (TTM)
-9.1
EPS (TTM)
-$1.50
52W Low $8.80High $32.71

Volume 1.38M

Average 0.99M

BBNX Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Beta Bionics, Inc.NASDAQ: BBNX

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of $623K fell 99.7% year over year, behind the -98.4% change in trailing-twelve-month financing cash flow. Sequentially, it fell 41.2% from the prior quarter. Over 3 fiscal years it compounded at +55.8% a year.

Context

  • Financing cash flow amounted to 214.3% of revenue in FY2025, up 128.9 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -99.7% toward the trailing-twelve-month pace of -98.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$623K-41.2% QoQ
Last fiscal yearDec 2025
$214.87M+286.4% YoY
LTMMar 2026
$4.38M-98.4% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.7%——
1 year+286.4%——
3-year CAGR+55.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
214.87M USD
Year-over-year change
+286.4%
3-year CAGR
+55.8%

Financing Cash Flow vs competitors

How BBNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -98.4% is the lowest of 7, against a peer median of +265.4%.
  • Financing cash flow amounts to 4.0% of revenue for BBNX, versus a peer median of 25.3%.
BBNX Competitors
Financing Cash Flow for BBNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 24.19B DKK+8.3%-18.1%7.3%
DXCMDexCom, Inc.LTM Jun 2026$2.33B USD+220.3%+45.1%46.9%
PODDInsulet CorporationLTM Jun 2026$845.4M USD+971.5%+145.4%27.7%
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026$514M USD—+57.0%16.0%
MNKDMannKind CorporationLTM Mar 2026$278.74M USD+310.5%+145.1%77.3%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$235.48M USD+2476.9%—22.9%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$15.14M USD-54.2%——
BBNXBeta Bionics, Inc.LTM Mar 2026$4.38M USD-98.4%+55.8%4.0%
Peer median (excluding BBNX) —+265.4%+57.0%25.3%

Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.75M)(44.1M)(54.76M)(73.2M)
Depreciation & Amortization2.09M2.09M2.28M2.88M
Deferred Income Tax0000
Stock-Based Compensation6.1M5.66M6.38M16.38M
Change in Working Capital(2.79M)(6.36M)(12.15M)(8.99M)
Accounts Receivables0(4.49M)(7.62M)(5.16M)
Inventory0(1.19M)(11.44M)(9.88M)
Accounts Payables(77K)716K1.52M2.1M
Other Working Capital(2.71M)(682K)5.39M3.95M
Other Non-Cash Items(854K)10.27M9.96M12.01M
Operating Cash Flow(60.21M)(32.45M)(48.27M)(50.93M)
Capital Expenditures(772K)(402K)(3.4M)(5.3M)
Acquisitions (Net)0000
Purchases of Investments0(69.3M)(72.13M)(327.51M)
Sales of Investments0072M170M
Other Investing Activities3K(69.29M)50K0
Investing Cash Flow(769K)(69.69M)(3.48M)(162.81M)
Debt Repayment0000
Common Stock Issued389K29K55.62M214.87M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities389K101.03M00
Financing Cash Flow56.78M101.03M55.62M214.87M
Effect of Forex Changes0000
Net Change in Cash(4.2M)(1.11M)3.87M1.14M
Free Cash Flow(60.98M)(32.85M)(51.67M)(56.22M)

Beta Bionics, Inc.

NASDAQ:BBNX

Intrinsic Alpha fair value

Locked

Current Price

$14.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.